EXPO:NASDAQExponent, Inc. Analysis
Data as of 2026-06-30 - not real-time
$59.70
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Exponent, Inc. (EXPO) is trading at $59.70, well above its DCF‑derived fair value of $32.48, indicating a significant premium. The stock sits just below its 20‑day SMA (≈$57.97) but under the 50‑day SMA (≈$60.26), and the 200‑day SMA remains at $67.76, signaling a bearish medium‑term trend. Technical momentum is mixed: the RSI of 54.7 suggests neutral pressure, while the MACD histogram is positive and the MACD line sits above its signal, hinting at a short‑term bullish tilt. Volume is increasing, yet volatility is high at 35.5% over the past 30 days, and beta of 0.62 points to lower market‑wide risk. Fundamentally, the company delivers solid profitability with a 19.8% net margin, 27.9× trailing P/E (below the industry average of 31.7×), and a 10.5% revenue growth rate. Cash generation is robust (free cash flow ≈$73.8 M) and the dividend yield of 2.04% is backed by a 56.5% payout ratio, supporting sustainability. Analyst consensus targets around $80 suggest a potential upside of roughly 36%, but the current price already reflects much of that optimism. The sector—engineering and construction consulting—is cyclically sensitive, adding moderate sector risk. Overall, EXPO offers a stable dividend and strong cash flow but appears overvalued relative to intrinsic calculations, requiring careful timing for entry.
Given the mixed technical signals, elevated price premium, and solid fundamentals, investors should weigh the upside potential against the valuation gap. A cautious stance—holding for dividend income while monitoring price action around key moving averages—may be prudent, with a view to re‑evaluate if the stock re‑aligns with its fair value or if broader market sentiment shifts.
Given the mixed technical signals, elevated price premium, and solid fundamentals, investors should weigh the upside potential against the valuation gap. A cautious stance—holding for dividend income while monitoring price action around key moving averages—may be prudent, with a view to re‑evaluate if the stock re‑aligns with its fair value or if broader market sentiment shifts.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price below 50‑day SMA indicating bearish bias
- Positive MACD histogram suggesting short‑term support
- Increasing volume amid high volatility
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Revenue growth of 10.5% and strong operating margins
- Analyst target median price near $80 implying upside
- Sustainable dividend yield of 2.04% with comfortable payout
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Robust ROE (~28%) and cash flow generation
- Low beta (≈0.62) reducing market‑wide volatility exposure
- Diversified consulting portfolio across multiple industries
Key Metrics & Analysis
Financial Health
Revenue Growth10.50%
Profit Margin19.76%
P/E Ratio27.9
ROE27.94%
ROA10.06%
Debt/Equity23.95
P/B Ratio8.6
Op. Cash Flow$123.5M
Free Cash Flow$73.8M
Industry P/E31.7
Technical Analysis
TrendBearish
RSI54.7
Support$54.07
Resistance$61.43
MA 20$57.97
MA 50$60.26
MA 200$67.76
MACDBullish
VolumeIncreasing
Fear & Greed Index89.91
Valuation
Fair Value$32.48
Target Price$81.67
Upside/Downside36.80%
GradeOvervalued
TypeBlend
Dividend Yield2.04%
Risk Assessment
Beta0.62
Volatility35.54%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.